Neoplasia/BPH

	Re: Nikita Sushentsev, Anne Y. Warren, Richard Colling, et al. Active Monitoring, Surgery, and Radiotherapy for Cribriform-positive and Cribriform-negative Prostate Cancer: A Secondary Analysis of the PROTECT Randomized Clinical Trial. JAMA Oncol. In press. https://doi.org/10.1001/jamaoncol.2025.4125. Eur Urol Focus Bernardino R, Le Guevélou J, Autorino R, Gandaglia G, Marra G, Young Academic Urologists Prostate Group. PMID: 41421931 [PubMed - as supplied by publisher]
	Re: Final Overall Survival and Safety Analyses of the Phase III PSMAfore Trial of [(177)Lu]Lu-PSMA-617 Versus Change of Androgen Receptor Pathway Inhibitor in Taxane-Naive Patients with Metastatic Castration-Resistant Prostate Cancer. Eur Urol Barata PC, Grier AL. PMID: 41421925 [PubMed - as supplied by publisher]
	Local and locoregional prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol Walz J, Attard G, Bjartell A, Blanchard P, Castro E, Compérat E, Emmett L, Fanti S, Fonteyne V, Foulon S, Gillessen S, Gravis G, James ND, Oprea-Lager DE, Ost P, Padhani A, Parker C, Renard-Penna RM, Rubin MA, Saad F, Sweeney C, Tilki D, Tombal B, Tree AC, Zilli T, Fizazi K, ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. PMID: 41421764 [PubMed - as supplied by publisher]
	Agent-Specific Differences in Sustained Intraoperative Hypotension during oral 5-Aminolevulinic Acid-Guided Transurethral Resection of Bladder Tumor: A Retrospective Observational Study. Photodiagnosis Photodyn Ther Katsumata Y, Yamamoto S, Iwata H, Kuroiwa H, Fukuhara H, Fukata S, Inoue K, Kawano T. PMID: 41421436 [PubMed - as supplied by publisher]
	Predictive value of quantitative parameters from dual-tracer FDG and PSMA PET/CT for progression to castration resistance in patients with metastatic hormone-sensitive prostate cancer. Eur J Radiol Xiang F, Zeng Y, Zhang Z, Zhang Y, Su W, Zhou M, Yu J, Luo C, Wu Y, Zheng F. PMID: 41421031 [PubMed - as supplied by publisher]
	Association of race and survival in patients treated with apalutamide: Pooled analysis of two phase 3 trials. Cancer Gebrael G, Agarwal N, Morgans AK, Vince R Jr, Swami U, Jia AY, Zaorsky N, Chehade CH, Ozay ZI, Malone S, Morgan SC, Wallis CJD, Kishan AU, Barata PC, Chowdhury S, Garcia JA, Sheng I, Brown JR, Small EJ, Sun Y, Shore ND, Saad F, Spratt DE, Roy S. PMID: 41420831 [PubMed - indexed for MEDLINE]
	Application of transurethral blue laser vaporization of the prostate in patients aged 80 and above: a single-center clinical analysis of 157 cases. Lasers Med Sci Wang C, Fu X, Ji Y, Cheng H, Wang S, Liu G, Fan Z, Qiao J, Xu X, Du Q. PMID: 41420775 [PubMed - indexed for MEDLINE]
	Retraction Note: Kidney cancer diagnosis and surgery selection by double Decker convolutional neural network from CT scans combined with great wall construction algorithm. Abdom Radiol (NY) Kumar H, Taluja A, Muniyandy E, Kolli S. PMID: 41420746 [PubMed - as supplied by publisher]
	Innovative AI model for bladder cancer diagnosis. Discov Oncol Jiang L, Ge W, Feng R, Ji L, Huo J, Li S, Fan T. PMID: 41420667 [PubMed - as supplied by publisher]
	Cellular Senescence in Kidney Diseases: From Bench to Clinic. FASEB J Shu S, Liu J, Yuan Q, Zhang C. PMID: 41420520 [PubMed - indexed for MEDLINE]
	Novel DNA methylation biomarkers in urine for non-invasive diagnosis of bladder urothelial carcinoma. Clin Epigenetics Shi C, Xu J, Chen Q, Gao X, Chen L, Jin C, Yu Z, Dou X. PMID: 41420251 [PubMed - indexed for MEDLINE]
	Discovery and validation of RAB3B as a diagnostic biomarker for prostate cancer with serum PSA below 10 ng/mL based on a multi-omics study. Cancer Cell Int Zhao C, Deng G, Chen J, Li H, Fan R, Fu Z, Ye D, Lai C, Di J. PMID: 41419883 [PubMed - as supplied by publisher]
	Construction and verification of a prognostic model for prostate cancer based on ribosome biogenesis-related genes. BMC Med Genomics Xie J, Tang Y, Wang Y, Gao X, Fu F, Liu Y, Yi C, Zhou G, Wang Z, Chen C, Jin P, Cai Y, Zhou J. PMID: 41419859 [PubMed - indexed for MEDLINE]
	Transperineal cognitive fusion MRI-targeted biopsy shows higher detection rates than systematic biopsy in prostate cancer: a prospective cohort study. BMC Urol Jiang J, Wang K, Xie X, Mo X, Fu Z, Wang Q, Qian F. PMID: 41419822 [PubMed - as supplied by publisher]
	Predictive Value of Prior Non-muscle-invasive Bladder Cancer for the Effectiveness of Neoadjuvant Chemotherapy in Localized Muscle-invasive Bladder Cancer: A Real-world Analysis of the BLADRAC Cohort. Eur Urol Oncol Grobet-Jeandin E, Diamant E, Gabriel PE, De Olivera A, Harber T, Colombel M, Hanquiez P, Chatain V, Vordos D, Duquesne I, Borz MB, Verhoest G, De Varennes AM, Surlemont L, Ghenassia M, Masson-Lecomte A, Peyrottes A, Lebacle C, Beniac P, Léon P, Larré S, Taha F, Marcq G, Szostek A, Pradere B, Calleris G, Xylinas E, Allory Y, Bajeot AS, Prost D, Audenet F, Thibault C, Rouprêt M, Roumiguié M, Seisen T. PMID: 41419411 [PubMed - as supplied by publisher]
	Exercise During or After Intravesical Therapy for Bladder Cancer: A Randomized Feasibility Trial. Semin Oncol Nurs Arthuso FZ, Fairey AS, Boulé NG, Jacobsen NE, Dean LW, Courneya KS. PMID: 41419398 [PubMed - as supplied by publisher]
	Therapy strategies to defeat prostate cancer heterogeneity. Semin Nucl Med Jadvar H, Iravani A. PMID: 41419380 [PubMed - as supplied by publisher]
	Strategies to Mitigate Breast-related Adverse Events in Patients with High-risk Biochemically Recurrent Prostate Cancer Receiving Enzalutamide Monotherapy: Perspectives and Challenges. Eur Urol Focus Shore ND, Freedland SJ, Horvath LG, O'Sullivan JM, Giorgi U, Ray EC, Ross AE, Tang Y, Russell D, Iwata KK, Rosales M, Ganguli A, Tombal B. PMID: 41419364 [PubMed - as supplied by publisher]
	Prognostic Factors of Trimodal Therapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. Eur Urol Focus Miyajima K, Matsukawa A, Yanagisawa T, Miszczyk M, Roessler N, Inoue S, Nishimura S, Alqahtani AS, Alfarhan AR, Urabe F, Mori K, Karakiewicz PI, Reis LO, Kimura T, Shariat SF. PMID: 41419363 [PubMed - as supplied by publisher]
	Antidiabetic Medications and Bladder Cancer Risk in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Endocr Pract Rao Y, Meng S, Yi-Wen Yu E, Chen Y, van Alebeek R, Al-Zalabani AH, Zeegers MP, Wesselius A. PMID: 41419174 [PubMed - as supplied by publisher]

Articles 1 - 20 / 184125

Page 1 of 9207



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy